Abstract
Iron content is increased in the substantia nigra of persons with Parkinson’s disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator defer...
Cite
CITATION STYLE
APA
Devos, D., Labreuche, J., Rascol, O., Corvol, J.-C., Duhamel, A., Guyon Delannoy, P., … Moreau, C. (2022). Trial of Deferiprone in Parkinson’s Disease. New England Journal of Medicine, 387(22), 2045–2055. https://doi.org/10.1056/nejmoa2209254
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free